RSP - On RAS drugs

Aus coViki
Wechseln zu: Navigation, Suche collects the really good Ideas and the scientific Record on Covid-19 Virus.

plus neprilysin inhib.
32282032 ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
32369103 ä. Sacubitril/valsartan in COVID-19 patients: the need for trials

32470547 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.

32328234 2020. Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?
32340096 2020. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension

beta arrestin
32412788 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.

AT(1-7), mas
32389847 2020. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19
32242749 2020. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?

other papers
32428864 2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
32492292 2020. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.

32236478 ä. Speculation is not evidence: antihypertensive therapy and COVID-19
32220930 2020. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19

32283158 ä. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis
32344190 ä. Debate on Drugs That May Aggravate COVID-19
32363137 ä. Anti-RAS drugs and SARS-CoV-2 infection
32370986 ä. Renin-angiotensin-aldosterone system and COVID-19 infection
32286678 2020. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19
32293003 ä. Hypertension, the renin?angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence
32215613 ä. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System?a Call for Epidemiologic Investigations
32339215 ä. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19
32332039 2020. Renin-angiotensin-aldosterone system inhibitors and COVID-19
32264922 2020. COVID-19 and the RAAS?a potential role for angiotensin II?
32213760 2020. Facts and reflections on COVID-19 and anti-hypertensives drugs
32303915 ä. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
32323279 2020. Renin-Angiotensin-System (RAS) und COVID-19 - Zur Verordnung von RAS-Blockern
32250244 2020. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
32324223 ä. Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence
32324222 ä. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19
32286607 ä. Might renin?angiotensin system blockers play a role in the COVID-19 pandemic?
32266708 ä. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
32274522 ä. Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection
32231220 ä. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
32233755 2020. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
32275190 2020. Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non?COVID-19 Sepsis but Carries a Moderately Increased Risk of Death
32291526 2020. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
32341442 ä. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors?lessons from available evidence and insights into COVID-19
32305401 ä. Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System
32233753 2020. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
32272142 ä. More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19
32227760 ä. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19
32304747 2020. Angiotensin receptor blockers and COVID-19
32246101 ä. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic
32358609 ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?
32292865 2020. COVID-19 and the Renin-Angiotensin System
32231328 ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
32203970 ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade
32311696 ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade?
C7151242 ä. Controversy regarding ACE inhibitors / ARBs in Covid-19
32241880 2020. Drugs and the renin-angiotensin system in covid-19
32282224 2020. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations
32302248 2020. ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection?
32302265 2020. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19
32286246 2020. COVID-19 infections are also affected by human ACE1 D/I polymorphism
32255491 2020. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19
32320478 2020. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence
32129518 ä. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
32359088 2020. RAAS blockers in hypertension posing a higher risk towards the COVID-19
32295811 2020. EMA advice on renin-angiotensin system medicines during covid-19 pandemic
32329083 2020. (ang.)COVID-19 transmission through host cell directed network of GPCR
32356926 2020. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19
32304146 2020. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections
32290680 2020. Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers
32310915 2020. ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2
32362297 ä. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
32340044 2020. The ACE-2 in COVID-19: Foe or Friend?
32208987 2020. Renin-angiotensin system (RAS) blockers and the COVID-19 pandemic: at present there is no evidence to abandon RAS blockers
32367746 2020. ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective
32348166 2020. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study

32301766 ä. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2

32371817 2020. Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?
32371814 2020. Response to four comments on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic??
32371812 2020. COVID-19, hypertension and angiotensin receptor-blocking drugs
32371810 2020. Comment on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic??
32351121 2020. Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder
32195824 2020. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
32374416 2020. ACE2 and prognosis of COVID-19 Insights from Bartter s and Gitelman s syndromes patients
32369211 2020. What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?
32330302 2020. Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19"
32221983 2020. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19
32266994 2020. Comment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19"
32369097 ä. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
32376099 ä. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
32324209 ä. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
32242890 2020. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

32242182 2020. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19

32356627 ä. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
32356625 ä. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19
32356628 ä. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
32267499 ä. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease
32164092 2020. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia
32283876 2020. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19
32189489 2020. ACE2 in the context of 2019-nCoV infection: friend or foe?

C7169649 2020. EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic

C7197241 2020. ACEI inhibitors and ARBs do not increase severity of COVID-19
C7183935 ä. Status of SARS-CoV-2 infection in patients on renal replacement therapy Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)?
32248854 ä. A potential protective role of losartan against coronavirus-induced lung damage
32414646 2020. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
32448641 ä. Bloqueantes del sistema renina-angiotensina e infeccion por COVID-19

32332868 ä. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels

32360010 2020. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic
32268149 2020. An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
32376099 2020. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
32456945 ä. Supresion de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica
32266375 ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality

32228222 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

32281055 ä. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

32220710 2020. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2
32034638 ä. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury

32251498 ä. Hypertension and COVID-19
32344395 2020. The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection
32196087 ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19?

32360703 ä. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications

32305506 ä. Renin-angiotensin system at the heart of COVID-19 pandemic
32299780 2020. Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19
32299779 ä. What is the Role of Angiotensin Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive, Diabetic Patients?
32301968 ä. Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications

32264791 2020. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

32220422 2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections

32336612 ä. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

32344526 2020. COVID-19 and RAS: Unravelling an Unclear Relationship

32399093 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
32501190 2020. Angiotensin converting enzyme 2 (ACE2) and COVID-19: using antihypertensive medications, pharmacogenetic considerations.
32461198 2020. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
32505834 2020. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
32394689 2020. COVID-19, Renin-angiotensin System and Hematopoiesis.
32432433 2020. Severity of COVID-19: The importance of being hypertensive.
32471831 2020. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".
32444383 2020. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
32401442 2020. Les bloqueurs du systeme renine-angiotensine-aldosterone en temps de pandemie Covid-19 : amis ou ennemis ?
32314329 2020. ACE-2 och coronavirus - en fraga om balans och dynamik?
32435607 2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.
32581256 2020. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
32425303 2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
32428811 2020. Exercise as medicine for COVID-19: An ACE in the hole?
32544884 2020. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2.
32542396 2020. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy.
32565362 2020. Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissues.
32564289 2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.
32583443 2020. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply.
32553928 2020. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
32575476 2020. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells.
32538738 2020. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
32546047 2020. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.
32602627 2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.

Meine Werkzeuge